Evidence map›Paper›PMID 41206806›Full record

ArticleEuropean journal of heart failure2025

Sodium-glucose co-transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular-kidney- metabolic conditions: A pooled analysis of randomized trials.

João Pedro Ferreira, Pedro Marques, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques-Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

João Pedro FerreiraRISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.ORCID https://orcid.org/0000-0002-2304-6138
Pedro MarquesRISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Stefan D AnkerDepartment of Cardiology (CVK) of German Heart Center Charité German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX and University of Mississippi, Jackson, MS, USA.
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
Abhinav SharmaResearch Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada.
Francisco Vasques-NóvoaRISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Luís MendonçaRISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
João Sérgio NevesRISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Milton PackerBaylor University Medical Center, Dallas, TX, USA.
Faiez ZannadUniversité de Lorraine, INSERM, Centre d'Investigations Cliniques, CHRU de Nancy, Inserm and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe efficacy of sodium-glucose co-transporter 2 inhibitors (SGLT2i) among patients with cardiovascular-kidney-metabolic (CKM) conditions who experience severe estimated glomerular filtration rate (eGFR) deterioration during follow-up is not well established. The aim of this study was to assess the risk of cardiovascular outcomes and mortality after eGFR deterioration to <25 ml/min/1.73 m METHODS AND

resultsPooled analysis of placebo-controlled trials: EMPEROR-Preserved, EMPEROR-Reduced, EMPA-REG OUTCOME, CANVAS-R, and CREDENCE. Time-updated models with stratification by study were used. The median follow-up to eGFR deterioration was 17 months and total follow-time was 29 months. Studied outcomes included heart failure hospitalization or cardiovascular mortality, the composite of cardiovascular mortality, stroke or myocardial infarction, and all-cause mortality. Overall, 26 946 patients were included, of these 1392 (5.2%) experienced eGFR deterioration to <25 ml/min/1.73 m

conclusionsSevere eGFR deterioration during follow-up was associated with an increased risk of subsequent cardiovascular events and mortality. SGLT2i reduced the probability and were beneficial irrespective of severe eGFR deterioration.

Indexed as

Cardiovascular DiseasesGlomerular Filtration RateRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsCardiovascular‐kidney‐metabolic conditionsKidney function deteriorationSodium–glucose co‐transporter 2 inhibitorsTreatment effect

Identifiers

PMID41206806
PMCPMC12765462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.